Downregulation and upregulation

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Retrieved on: 
星期四, 五月 9, 2024
NK, Immunotherapy, Safety, Gene silencing, Rationalization, Research, Cell, Conference, Merkel-cell carcinoma, Downregulation and upregulation, NCT, Skin, Patient, Fox Business, Gene, Hyperpigmentation, Society, Patent, Melanoma, TYR, File, Angela Merkel, Vaccine

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.

Key Points: 
  • MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.
  • At March 31, 2024, we had cash of $6.5 million as compared with $8.5 million at December 31, 2023.
  • Net loss was $2.2 million for the three months ended March 31, 2024 as compared with $3.6 million for the three months ended March 31, 2023.
  • The decrease in net loss was primarily due to the changes in research and development expenses, as described above.

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Retrieved on: 
星期四, 五月 9, 2024
Sale, TNF, Phase, DSM-IV codes, Patient, MUC4, CD47, Pacific Rim, CTLA4, LAG3, Research, Tumor microenvironment, Conference, Downregulation and upregulation, Disease, Exercise, Chemistry, SRC, Macrophage, BOCA, TIGIT, Treatment-resistant depression, Neuroinflammation, Neoplasm, Deficit spending, TME, Pharmaceutical industry

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
  • INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Financial Results for the First Quarter Ended March 31, 2024:
    Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.
  • Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

Retrieved on: 
星期一, 五月 6, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ISH, PSMA, CD3, CA9, Payload, CRISPR, SPA, Risk, Tissue, ICT, Abstract, Immunosuppression, Cytokine, Tumor microenvironment, Cell, Research, Primer, Downregulation and upregulation, Engineering, DNA, Science, Gene, Society, Neoplasm, Antigen, Messenger, Information and communications technology, Immune system, Kidney cancer, In situ hybridization, Ovarian cancer, Vaccine

These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).

Key Points: 
  • These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).
  • It integrates an “AND” logic gate designed to limit off-tumor toxicity through a requirement for dual tumor antigen recognition.
  • T cell exhaustion from chronic antigen stimulation and an immunosuppressive tumor microenvironment limits the efficacy of T cell therapies used to treat solid tumors.
  • This research used CRISPR/Cas9-based screening, paired with deep sequencing, to identify intrinsic genetic perturbations that can prevent T cell exhaustion.

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on: 
星期一, 四月 8, 2024
MDM2, Apoptosis, ASH, Drug discovery, PD, Patient, Tumor microenvironment, Cancer, Doctor of Philosophy, TPD, Proteomics, AACR, Society, Therapy, Drug development, Downregulation and upregulation, VHL, STAT3, Pharmaceutical industry

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Key Points: 
  • For these reasons, STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies.
  • Additionally, this unique mechanism of action led to induction of proinflammatory anti-tumorigenic transcriptional signatures in the tumor microenvironment.
  • This has resulted in robust antitumor activity in patients, as reported in the Company’s latest clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2023.
  • The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
星期五, 三月 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期五, 四月 5, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, PDT, Macrophage, Downregulation and upregulation, Ovarian cancer, BRCA, ECM, Pericyte, Apoptosis, Nanoparticle, Cervical cancer, GBM, Patient, Neoplasm, Doxorubicin, Traffic barrier, Cancer, Triple-negative breast cancer, Proteomics, AACR, Glioblastoma, Pancreatic cancer, Phenotype, PARP, Cisplatin, Immunogenic cell death, Large intestine, TNBC, Animal, PDGFR, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
  • Presentations from Novocure-sponsored and partner programs include:
    Tumor Treating Fields (TTFields) targeted self assembling nanoparticles for pancreatic cancer treatment: In vitro and in vivo assessment.
  • Tumor Treating Fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model.
  • Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib.

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
星期三, 三月 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
星期三, 二月 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
星期三, 二月 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Retrieved on: 
星期一, 十二月 18, 2023
Patient, Map, Downregulation and upregulation, KAT, Kronos, Research, SYK, CDK9, Dana–Farber Cancer Institute, CRH, Disease, Multiple myeloma, SAN, KRON, White noise, Infection, Cancer, IRF4, TRN, AML, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company has decided not to proceed to phase 2. The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.

Key Points: 
  • The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.
  • Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN).
  • “Kronos Bio was founded with a clear vision: to tackle the challenge of deregulated transcription, a hallmark of cancer,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • We look forward to continuing to work with the Kronos Bio team to bring KB-9558 to patients.”
    “We believe that KB-9558 is positively differentiated from compounds targeting other p300 domains,” said Christopher Dinsmore, Ph.D., chief scientific officer of Kronos Bio.